IP rights have nothing to do with slow global rollout of vaccines
Despite this, some 90 developing nations, led by India and SA, have called for a waiver to suspend all intellectual property rights associated with Covid-19 innovations
17 March 2021 - 05:00
In the face of a Covid-19 pandemic that has caused 2.6-million fatalities worldwide, life sciences companies have raced to bring forward a wide range of life-saving innovations, including novel diagnostic tests such as that of LumiraDx, which can detect the virus within minutes; therapeutics, such as Gilead Science’s remdesivir; and highly effective vaccines such as those from Moderna, Pfizer-BioNTech, and Johnson & Johnson.
More than 600 novel Covid-19 treatments are under development, including 130 vaccines in global clinical trials and 176 in pre-clinical trials...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.